Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26373405 | 1.00 | DUT (0.56) | DUTP2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL26133860 | 1.00 | DUT (0.56) | DUTP2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL26373418 | 1.00 | DUT (0.56) | DUTP2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL24782135 | 1.00 | DUT (0.56) | DUTP2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL10391187 | 1.00 | DUT (0.56) | DUTP2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL24781265 | 1.00 | DUT (0.56) | DUTP2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL25399227 | 0.92 | DUT (0.56) | DUTP2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL21089723 | 0.92 | DUT (0.56) | DUTP2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL780745 | 0.92 | DUT (0.56) | DUTP2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL780746 | 0.92 | DUT (0.56) | DUTP2RY6P2RY14SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | disclosed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | disclosed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | DUT 16/4885P2RY6 141/4885P2RY14 161/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | DUT 16/4885P2RY6 141/4885P2RY14 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.